ALLEGRA-DÂ® 12 HOUR (fexofenadine hydrochloride and pseudoephedrine hydrochloride)
Extended-Release Tablets for oral administration contain 60 mg fexofenadine
hydrochloride for immediate release and 120 mg pseudoephedrine hydrochloride
for extended release. Tablets also contain as excipients: microcrystalline
cellulose, pregelatinized starch, croscarmellose sodium, magnesium
stearate, carnauba wax, stearic acid, silicon dioxide, hypromellose
and polyethylene glycol.
ALLEGRA-D 12 HOUR Extended-Release
Tablets are indicated for the relief of symptoms associated with seasonal
allergic rhinitis in adults and children 12 years of age and older.
Symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/
and/or throat, itchy/watery/red eyes, and nasal congestion.
ALLEGRA-D 12 HOUR should be administered
when both the antihistaminic properties of fexofenadine hydrochloride
and the nasal decongestant properties of pseudoephedrine hydrochloride
are desired (see CLINICAL
Clinical Trials Related to Allegra D-12 Hour (Fexofenadine / Pseudoephedrine)
Topical Treatment of Under Eye Dark Circles and Swelling [Recruiting]
This study examines topical treatment of under eye circles and swelling.
Pregabalin for the Treatment of Uremic Pruritus [Not yet recruiting]
Pruritus s a very distressing problem affecting patients with uremia and the prevalence of
uremic pruritus (UP) ranges between 22% to 66%. Although some studies suggested pruritus is
being decreased recently by use of better dialysis techniques, accumulating studies have
shown the still high prevalence of UP. Because of its long duration, frequency and high
intensity, UP has been reported to have a negative impact upon the patients' quality of life
(QoL). However, the therapies in use, including antihistamines, ultraviolets, opioid
antagonists and topical agents, are generally of insufficient efficacy, failing to provide
adequate and long-lasting relief. Based on the neuropathic hypothesis and frequent
co-occurrence of chronic pruritus and peripheral neuropathy in the patients undergoing
hemodialysis, gabapentin, a medication widely used for a spectrum of neuropathic pain
syndromes, has recently been suggested to be effective in the treatment of UP. Pregabalin,
another gabaergic drug structurally related to gabapentin, have an advantage over gabapentin
in terms of its more rapid response to stressful symptoms. Only two very recently
small-scaled studies evaluate the effect of pregabalin for UP. However, both these studies
were not randomized, placebo-controlled trails. As UP is still one of the most vexing and
disabling symptoms in patients with ESRD, we decided to do this multicenter, randomized
double-blind placebo-controlled trial (RCT) with a larger sample size and a longer duration.
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot [Recruiting]
Phenotyping is an approach largely used for the evaluation of the activity of cytochromes
and transporters in vivo. It consists of the administration of probe substances metabolised
by a specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by
the determination of a metabolic ratio or the evaluation of the plasmatic or urinary
concentrations of the probe substances. The administration of a cocktail containing several
probe substances allows the simultaneous evaluation of the activity of several cytochromes
and P-gp in a single test.
The aim of this project is the validation of a phenotyping cocktail of low dose probe drugs
for the assessment of cytochrome P450 and P-gp activities by simple capillary blood sampling
and dried blood spot (DBS) analysis. The cocktail consists of caffeine, bupropion,
flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous
phenotyping of CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.
The modulation of the activity of cytochromes or P-gp will be evaluated by the
administration of inhibitors (fluvoxamine, voriconazole, quinidine) or inducer (rifampicin)
of the metabolic pathways or the P-gp mediated transport.
Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis [Recruiting]
Recruitment of at least 10 adult patients (men and women) among individuals affected and
admitted to the hospitals identified for the clinical study. All patients shall be between
18 and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During
therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's
visits (day 1,3,7,10,14,21, and 28).
Age- Versus Ovarian Reserve Markers - Based Therapy in In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles [Recruiting]
This randomized controlled trial has been designed for carrying out a comparison of new AMH
(Anti-Müllerian Hormone)-based individualized treatment (using a nomogram) with the wide
accepted age-based strategy. The main objective of the trial is to assess whether an
individualized FSH starting dose can increase the rate of women with an adequate ovarian
response in terms of retrieved oocytes (optimal number of retrieved oocytes: 5-14).
Page last updated: 2009-12-08